| Chesapeake Shores | |
| 21412 Great Mills Road, Lexington Park, Maryland 20653 | |
| (301) 863-7244 | |
| Name | Chesapeake Shores |
|---|---|
| Location | 21412 Great Mills Road, Lexington Park, Maryland |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 125 |
| Occupancy Rate | 73.12% |
| Medicare ID (CCN) | 215142 |
| Legal Business Name | Lp Lexington Park Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1588855860 |
| Organization Name | LP LEXINGTON PARK LLC |
| Doing Business As | CHESAPEAKE SHORES |
| Address | 21412 Great Mills Rd, Lexington Pk, MD 20653 |
| Phone Number | 301-863-7244 |
News Archive
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
New research indicates that a diagnostic strategy using computed tomographic pulmonary angiography (CTPA) may be a safe alternative to conventional lungs scans (known as ventilation-perfusion scans) for excluding the diagnosis of pulmonary embolism (blood clots in the lung vessels), although CTPA may detect more clots, according to a study in the current issue of JAMA: The Journal of the American Medical Association.
SRI International, an independent nonprofit research and development organization, announced today it has been awarded a grant by the Department of Energy (DOE) to expand its MetaCyc database and enhance its Pathway Tools software. This project will give SRI's bioinformatics tools even greater utility in the emerging area of bioenergy, or renewable energy derived from biological sources.
Small Island Developing States are among the most vulnerable nations to climate change in the world. Yet, many island states are also leading in the global response to climate change, through ambitious emissions reduction targets, adaptation actions, and developing climate resilient health systems.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
› Verified 3 days ago
| NPI Number | 1598745200 |
| Organization Name | HQM OF BAYSIDE, LLC |
| Doing Business As | BAYSIDE CARE CENTER AT LEXINGTON PARK |
| Address | 21412 Great Mills Rd, Lexington Pk, MD 20653 |
| Phone Number | 301-863-7244 |
News Archive
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
New research indicates that a diagnostic strategy using computed tomographic pulmonary angiography (CTPA) may be a safe alternative to conventional lungs scans (known as ventilation-perfusion scans) for excluding the diagnosis of pulmonary embolism (blood clots in the lung vessels), although CTPA may detect more clots, according to a study in the current issue of JAMA: The Journal of the American Medical Association.
SRI International, an independent nonprofit research and development organization, announced today it has been awarded a grant by the Department of Energy (DOE) to expand its MetaCyc database and enhance its Pathway Tools software. This project will give SRI's bioinformatics tools even greater utility in the emerging area of bioenergy, or renewable energy derived from biological sources.
Small Island Developing States are among the most vulnerable nations to climate change in the world. Yet, many island states are also leading in the global response to climate change, through ambitious emissions reduction targets, adaptation actions, and developing climate resilient health systems.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
New research indicates that a diagnostic strategy using computed tomographic pulmonary angiography (CTPA) may be a safe alternative to conventional lungs scans (known as ventilation-perfusion scans) for excluding the diagnosis of pulmonary embolism (blood clots in the lung vessels), although CTPA may detect more clots, according to a study in the current issue of JAMA: The Journal of the American Medical Association.
SRI International, an independent nonprofit research and development organization, announced today it has been awarded a grant by the Department of Energy (DOE) to expand its MetaCyc database and enhance its Pathway Tools software. This project will give SRI's bioinformatics tools even greater utility in the emerging area of bioenergy, or renewable energy derived from biological sources.
Small Island Developing States are among the most vulnerable nations to climate change in the world. Yet, many island states are also leading in the global response to climate change, through ambitious emissions reduction targets, adaptation actions, and developing climate resilient health systems.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 15.08 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.95 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 40.62 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.69 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.49 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.94 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 1.11 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.6 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 90.86 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.92 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 59.78 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.84 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 30.82 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 11.48 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 12.5 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.5 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 81.45 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 73.64 | 82.93 |
News Archive
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
New research indicates that a diagnostic strategy using computed tomographic pulmonary angiography (CTPA) may be a safe alternative to conventional lungs scans (known as ventilation-perfusion scans) for excluding the diagnosis of pulmonary embolism (blood clots in the lung vessels), although CTPA may detect more clots, according to a study in the current issue of JAMA: The Journal of the American Medical Association.
SRI International, an independent nonprofit research and development organization, announced today it has been awarded a grant by the Department of Energy (DOE) to expand its MetaCyc database and enhance its Pathway Tools software. This project will give SRI's bioinformatics tools even greater utility in the emerging area of bioenergy, or renewable energy derived from biological sources.
Small Island Developing States are among the most vulnerable nations to climate change in the world. Yet, many island states are also leading in the global response to climate change, through ambitious emissions reduction targets, adaptation actions, and developing climate resilient health systems.
Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.
› Verified 3 days ago
Chesapeake Shores Location: 21412 Great Mills Road, Lexington Park, Maryland 20653 Phone: (301) 863-7244 |